Prescribing information



TAFINLAR® in combination with MEKINIST® is indicated in adult patients for the treatment of BRAF V600 positive, unresectable or metastatic melanoma, and in the adjuvant setting for Stage III BRAF V600 positive melanoma, following complete resection.1,2

Please refer to the respective SmPCs for all licensed indications.

Please use the buttons below to find out more about melanoma diagnosis and staging, and TAFINLAR® and MEKINIST® mode of action, efficacy, safety profile and patient management.


  1. Tafinlar (dabrafenib) Summary of Product Characteristics.
  2. Mekinist (trametinib) Summary of Product Characteristics.
Rate this content: 
Average: 4.5 (2 votes)
UK | September 2023 | 293938

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]